"Cystadenoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
| Descriptor ID |
D018293
|
| MeSH Number(s) |
C04.557.470.035.320.240 C04.557.470.590.485.240
|
| Concept/Terms |
Cystadenoma, Serous- Cystadenoma, Serous
- Cystadenomas, Serous
- Serous Cystadenoma
- Serous Cystadenomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenoma, Serous".
This graph shows the total number of publications written about "Cystadenoma, Serous" by people in this website by year, and whether "Cystadenoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystadenoma, Serous" by people in Profiles.
-
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res. 2024 May 01; 30(9):1750-1757.
-
Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology. 2023 01; 164(1):117-133.e7.
-
Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. Am J Gastroenterol. 2019 09; 114(9):1539-1549.
-
Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. Histopathology. 2019 Mar; 74(4):638-650.
-
Pancreatic surgery for tumors in children and adolescents. Pediatr Surg Int. 2016 Aug; 32(8):779-88.
-
Pancreatic Cystic Neoplasms: An Update. Gastroenterol Clin North Am. 2016 Mar; 45(1):67-81.
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
-
Clinical decision making in the management of pancreatic cystic neoplasms. Expert Rev Gastroenterol Hepatol. 2013 May; 7(4):353-60.
-
851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012 Sep; 152(3 Suppl 1):S4-12.
-
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012 Sep 01; 18(17):4713-24.